Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Experiments with fruit quality improvement lead to new approach for halting spread of cancer cells

05.07.2006
Experimental work aimed at improving the quality of fruit has led to the discovery by Hebrew University of Jerusalem agricultural researchers of a promising new avenue of drug treatment for halting the growth and spread of cancer cells in animals and humans.

Their approach has been shown to inhibit the malignant cells without affecting normal cells and without the severe side effects of traditional treatments such as radiation and chemotherapy. The strategy involves isolating the malignant tumor from its nutritional and oxygen supplies, thereby halting its growth and stopping metastases (spread of cancer cells to other parts of the body).

The work on the project was carried out at the Hebrew University Faculty of Agricultural, Food and Environmental Quality Sciences in Rehovot by Prof. Oded Shoseyov, Dr. Levava Roiz, Dr. Patricia Smirnoff and Dr. Betty Schwartz. Their discoveries were published recently in the journal Cancer of the American Cancer Society.

The approach of the Hebrew University researchers is based on the actions of actibind, a protein that is produced by the black mold Aspergillus niger and that is a well-known microorganism used in bio and food technology. In plants, actibind binds actin, a major component of the intracellular structure in plants, interfering with the plants' pollen tubes and halting cell growth.

While the Hebrew University researchers were initially interested in the activity of actibind in connection with a horticultural project aimed at improving the quality of peaches and nectarines, an actibind-like protein, RNaseT2, was also subsequently found to bind actin in human and animal migrating cells, such as the cells that are responsible for new blood vessel formation (angiogenesis) in tumors.

By blocking the blood supply to the tumors, actibind halted the ability of malignant cells to move through the blood stream to form new metastases. A further plus is that actibind is not toxic to normal cells, thereby significantly minimizing the risk of side effects.

In laboratory experiments using cell cultures that originated from human colon cancer, breast cancer and melanoma, increasing the level of actibind was found to reduce the ability of these cells to form tumorogenic colonies. Further experimentation, with a variety of animal models, showed that the increased actibind inhibited the growth of colon cancer-derived tumors, metastases and blood vessel formation. These promising discoveries were detailed in the Cancer article.

The results shown in working with actibind led to a further development in the researchers' project. During the completion of the human genome project, the gene encoding for RNaseT2, the human actibind-like protein, was found on chromosome 6. The Hebrew University team used genetic engineering procedures to produce a recombinant RNaseT2 protein that showed an impressive anti-cancer potential. These results have raised broad interest in international scientific meetings and in business circles.

The fungal actibind and the human RNaseT2 represent the basis for a new class of drugs that could be used as a front-line therapy in the fight against cancer, say the researchers.

Jerry Barach | EurekAlert!
Further information:
http://www.huji.ac.il

More articles from Agricultural and Forestry Science:

nachricht Climate change, population growth may lead to open ocean aquaculture
05.10.2017 | Oregon State University

nachricht New machine evaluates soybean at harvest for quality
04.10.2017 | University of Illinois College of Agricultural, Consumer and Environmental Sciences

All articles from Agricultural and Forestry Science >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Ocean atmosphere rife with microbes

17.10.2017 | Life Sciences

Neutrons observe vitamin B6-dependent enzyme activity useful for drug development

17.10.2017 | Life Sciences

NASA finds newly formed tropical storm lan over open waters

17.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>